Clinical Trials Browser

Phase 3 × INDUSTRY × osimertinib × Clear all

NCT06417814 2026-03-02

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-02-27

LAURA

Phase 3 Active not recruiting

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

NSCLC Patients With Brain Metastasis

NCT04487080 2026-02-04

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT07376382 2026-02-02

SYNSTAR-02

Phase 3 Not yet recruiting

NSCLC

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04765059 2026-01-13

COMPEL

Phase 3 Active not recruiting

98 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05120349 2026-01-12

ADAURA2

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT02511106 2026-01-05

ADAURA

Phase 3 Active not recruiting

682 enrolled 20 charts 2 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT05629234 2025-12-24

ROSY-T

Phase 3 Active not recruiting

Neoplasms

NCT06670196 2025-12-05

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06350097 2025-11-17

TROPION-Lung14

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

Phase 3 Active not recruiting

587 enrolled 44 charts 1 FDA

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05015608 2025-05-23

SACHI

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05261399 2025-01-10

SAFFRON

Phase 3 Recruiting

Carcinoma, Neoplasm Metastasis

NCT06735391 2024-12-16

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3 Recruiting

Locally Advanced or Metastatic Non-squamous NSCLC

NCT02454933 2024-09-19

CAURAL

Phase 3 Completed

29 enrolled 10 charts

Locally Advanced or Metastatic EGFR T790M+ NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3 Recruiting

NSCLC